EMA Authorised: Rasilez (aliskiren) — Lxo Ireland Designated Activity Company

View source ↗

Summary

The EMA has authorised Rasilez (aliskiren) for the treatment of hypertension; the marketing authorisation holder is Lxo Ireland Designated Activity Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Rasilez (aliskiren)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Lxo Ireland Designated Activity Company. Decision date: 06/02/2026